Targeting the assembly of the human immunodeficiency virus type I.
In the rush to develop anti-viral drugs against the human immunodeficiency virus type I (HIV-1), all the steps of the viral life cycle are potential targets of therapeutic intervention. In this review, we will explore the recent advances on strategies that aim at obstructing the formation, the release and the infectivity of newly formed virion particles from HIV-1 infected cells.
Muriaux
D
D
Unité INSERM 412, LaboRétro, Ecole Normale Supérieure de Lyon, IFR 128 Biosciences Lyon-Gerland, France. acimarel@ens-lyon.fr
Darlix
J L
JL
Cimarelli
A
A
D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology*; D002462:Cell Membrane / Q000378:metabolism / Q000821:virology; D015683:Gene Products, gag / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D006801:Humans; D014771:Virion / Q000187:drug effects* / Q000502:physiology; D019065:Virus Assembly / Q000187:drug effects*
D019380:Anti-HIV Agents; D015683:Gene Products, gag